Bioheart Expands Clinical Trials of Adult Myogenic Stem Cell Treatment for Heart Attack and Advanced Heart Failure Patients
16th Nov 2006, 19:41 GMT
. Bioheart a biotech company focused on the development of innovative cell therapies designed to repair areas of damaged muscle tissue in a patient's heart and improve cardiac function, is expanding its US and European clinical trials of its MyoCell adult myogenic stem cell composition and MyoCath needle-injection catheter product candidates.
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress